Aerosolised prostacyclin for pulmonary hypertension in neonates. 1994

L Bindl, and H Fahnenstich, and U Peukert
Centre for Paediatrics, University of Bonn, Germany.

Aerosolised prostacyclin (PGI2) was administered to two neonates with pulmonary hypertension to dilate the pulmonary vessels selectively. The alveolar-arterial oxygen gradient fell from 73.2 (patient 1) and 71.8 kPa (patient 2) to 33.8 and 26.7 kPa respectively. Systemic blood pressure remained stable while pulmonary blood pressure declined in patient 1. When inhaled, PGI2 seems to improve oxygenation, mainly due to reduction of intrapulmonary shunting.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007234 Infant, Premature A human infant born before 37 weeks of GESTATION. Neonatal Prematurity,Premature Infants,Preterm Infants,Infant, Preterm,Infants, Premature,Infants, Preterm,Premature Infant,Prematurity, Neonatal,Preterm Infant
D007235 Infant, Premature, Diseases Diseases that occur in PREMATURE INFANTS.
D008297 Male Males
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000336 Aerosols Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents. Aerosol
D014655 Vascular Resistance The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT. Peripheral Resistance,Total Peripheral Resistance,Pulmonary Vascular Resistance,Systemic Vascular Resistance,Peripheral Resistance, Total,Resistance, Peripheral,Resistance, Pulmonary Vascular,Resistance, Systemic Vascular,Resistance, Total Peripheral,Resistance, Vascular,Vascular Resistance, Pulmonary,Vascular Resistance, Systemic

Related Publications

L Bindl, and H Fahnenstich, and U Peukert
June 1999, Schweizerische medizinische Wochenschrift,
L Bindl, and H Fahnenstich, and U Peukert
January 2003, The Cochrane database of systematic reviews,
L Bindl, and H Fahnenstich, and U Peukert
November 1980, Lancet (London, England),
L Bindl, and H Fahnenstich, and U Peukert
January 2002, The Cochrane database of systematic reviews,
L Bindl, and H Fahnenstich, and U Peukert
May 2019, The Cochrane database of systematic reviews,
L Bindl, and H Fahnenstich, and U Peukert
January 2000, Annals of internal medicine,
L Bindl, and H Fahnenstich, and U Peukert
April 2005, The Cochrane database of systematic reviews,
L Bindl, and H Fahnenstich, and U Peukert
October 1993, Lancet (London, England),
L Bindl, and H Fahnenstich, and U Peukert
January 2020, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG,
L Bindl, and H Fahnenstich, and U Peukert
December 1997, Annals of internal medicine,
Copied contents to your clipboard!